CN Bio Innovations develop organ-on-chip and microfluidic technologies which enable scientists to grow miniature models of human organs in the lab. As well as academic partners, our systems are used by many of the Top 20 pharmaceutical companies for their drug discovery and drug safety programs. Additionally, our innovative platforms are currently being evaluated by the FDA as a validation tool for new drug applications.
Our platform recreates the physiological and mechanical micro-environment of organs inside the human body as well as permitting long-term culture of various cell types. CN Bio have also successfully developed organ-on-chip disease models such as NASH and HBV infection.
Our technologies support research scientists who are looking for data-rich in vitro platforms that can produce more human-relevant and accurate data to investigate a wide range of applications in oncology, infectious diseases, preclinical discovery &diagnostics and gene therapies.